Revolution Medicines (RVMD) Operating Margin (2019 - 2023)

Revolution Medicines' Operating Margin history runs 5 years deep, the most recent figure standing at 24256.47% for Q4 2023.

• In Q4 2023, Operating Margin fell 2385394.0% year-over-year to 24256.47%; the TTM figure through Sep 2024 stood at 88031.94% (down 8662217.0% YoY), while the FY2023 annual figure was 4207.12%, down 347711.0% from the prior year.
• Operating Margin for Q4 2023 stood at 24256.47%, down from 2845.11% in the prior quarter.
• The five-year high for Operating Margin was 79.26% in Q1 2019, with the low at 24256.47% in Q4 2023.
• The 5-year median for Operating Margin is 402.52% (2022), against an average of 2109.23%.
• The sharpest annual moves came in 2022 and 2023: Operating Margin surged 254813 bps in 2022, then plunged 2385394 bps in 2023.
• Revolution Medicines' Operating Margin stood at 161.85% in 2019, then plunged by 141 bps to 389.44% in 2020, then tumbled by 44 bps to 559.33% in 2021, then grew by 28 bps to 402.52% in 2022, then tumbled by 5926 bps to 24256.47% in 2023.
• Business Quant data shows RVMD's Operating Margin at 24256.47% in Q4 2023, 2845.11% in Q2 2023, and 1071.53% in Q1 2023.